Overview
Status
Active
Registry date
2021-01-28
Share capital
5,000.00 PLN
Financials
Revenue history
Financial insight
- The statement flags a going concern risk. brak zagrożenia
Filing timeliness
4 of 5 financial statements were filed late (the longest delay 752 days for 2022).
- 202510/07/2026
- 202405/08/2025
- 202305/08/2025
- 202205/08/2025
- 202130/09/2022
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Industry
Authorized Representatives
Mariusz Paweł Gawinage 52 – Management Board Member
Natalia Pawlakage 28 – Attorney-in-fact (sole)
Manner of representation
In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Mariusz Paweł Gawinage 52 | 75 | $1,012.97 | 75% |
Natalia Pawlakage 28 | 25 | $337.66 | 25% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2024-04-18.
09 1020 5402 0000 0402 0462 6505
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Feb 1, 2021 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $9,821$9,821 | Polska Fundacja Ośrodków Wspomagania Rozwoju Gospodarczego Oic Poland z Siedzibą w Lublinie |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Centrum Innowacji i Wdrożeń Bio-Inwestsp. z o.o. | $1,262,872.91 | bio-inwest.pl | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| Luna Laboratorysp. z o.o. | $61,894.23 | lunalab.pl | ||
| GenomtecS.A. | $54,746.36 | genomtec.com | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| Immbionicsp. z o.o. | $31,756.23 | immbionic.com.pl | ||
| Detoxedsp. z o.o. | $11,972.37 | detoxed.pl | ||
| Passio Biomaterialssp. z o.o. | $0.00 | passio.pl | ||
| BioencaS.A. | $0.00 | bioenca.pl | ||
| Dystrogen TherapeuticsS.A. | – | dystrogen.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-12-12 | Address change (Ul. Podgórna 50, 65-246, Zielona Góra → Ul. Sulechowska 1, 65-022, Zielona Góra) | |
| 2024-03-26 | Address change (Lublin → Ul. Podgórna 50, 65-246, Zielona Góra) | |
| 2022-07-14 | Address change (Ul. Fryderyka Chopina 41/2, 20-023, Lublin → Lublin) | |
| 2021-06-11 | Address change (Ul. Gospodarcza 26, 20-213, Lublin → Ul. Fryderyka Chopina 41/2, 20-023, Lublin) | |
| 2021-01-28 | Entered in the register |
FAQ
The main business activity of Selkis focuses on research and experimental development on biotechnology.
The company was registered in the Polish National Court Register (KRS) on January 28, 2021.
The headquarters is located at: ul. Sulechowska 1, 65-022 Zielona Góra.
The management board consists of: Mariusz Paweł Gawin (Member of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
In 2024, the company generated total revenue of $0, representing an increase of 51.4% compared to 2023.
No, the company recorded a net loss of $1,956 in 2024. For comparison, in 2023 the loss was $1,508, meaning the company increased its loss by 23.2%.
The largest operating cost category falls under external services. This category amounted to $1,955 in 2024, representing 100% of all operating expenses.
Last updated: 2026-10-07